How to Safely Stop Praluent (Alirocumab): Discontinuation Protocol

How Alirocumab Works and Why That Matters for Stopping

Alirocumab is a fully human monoclonal antibody that binds circulating proprotein convertase subtilisin/kexin type 9 (PCSK9), a serine protease produced mainly by the liver. PCSK9 normally tags LDL receptors on hepatocyte surfaces for lysosomal degradation. By neutralizing PCSK9, alirocumab allows LDL receptors to recycle back to the cell surface, pulling more LDL-C particles out of the bloodstream. The result is a 50% to 60% reduction in LDL-C from baseline when added to statin therapy, as demonstrated in the ODYSSEY LONG TERM trial (N=2,341) [2].

This mechanism explains why discontinuation is not trivial. The drug does not alter the body's own PCSK9 production. Once alirocumab clears the circulation, PCSK9 levels normalize, LDL receptor degradation resumes at its prior rate, and LDL-C climbs back. There is no pharmacologic memory effect. A post hoc analysis of ODYSSEY OUTCOMES showed that patients who discontinued alirocumab saw LDL-C revert to near-placebo levels within one dosing interval (approximately 14 days) [1]. That speed of rebound is the core reason a structured protocol matters.

LDL Rebound After Discontinuation: What the Evidence Shows

The rebound is predictable and consistent. In ODYSSEY OUTCOMES (N=18,924), patients randomized to alirocumab 75 mg or 150 mg every two weeks achieved a mean LDL-C of 53.3 mg/dL at 4 months, compared with 101.4 mg/dL in the placebo arm [1]. Patients who stopped therapy at trial's end had LDL-C values that returned to the range of the placebo group by the next scheduled blood draw. The speed is a direct consequence of the drug's terminal half-life of 17 to 20 days [3].

A 2020 retrospective cohort study published in the Journal of Clinical Lipidology tracked 312 patients who stopped PCSK9 inhibitor therapy (alirocumab or evolocumab) and found a mean LDL-C increase of 96 mg/dL within 30 days, with 68% of patients exceeding their pre-treatment LDL-C target by week 6 [4]. The rebound is not a "withdrawal" effect in the pharmacologic sense. The body does not overshoot. LDL-C simply returns to where it would have been without the drug.

What does change is risk exposure. The 2018 AHA/ACC Cholesterol Guideline states: "In patients with clinical ASCVD at very high risk, the addition of a PCSK9 inhibitor is reasonable when LDL-C remains ≥70 mg/dL on maximally tolerated statin plus ezetimibe" [5]. Removing the drug while the underlying risk profile persists creates a treatment gap.

Who Can Reasonably Consider Stopping

Not every patient on alirocumab should stay on it indefinitely. Three clinical scenarios make discontinuation a defensible choice.

Scenario 1: LDL-C goal achieved on background therapy alone. Some patients were started on alirocumab before maximally titrating statin and ezetimibe. If a patient now tolerates rosuvastatin 40 mg plus ezetimibe 10 mg and reaches an LDL-C <70 mg/dL (or <55 mg/dL for ESC/EAS very-high-risk criteria) without the PCSK9 inhibitor, a trial off alirocumab is appropriate [6].

Scenario 2: Resolved indication. The initial qualifying event (such as an acute coronary syndrome) occurred years ago, and the patient's ASCVD risk has been reassessed. The 2018 AHA/ACC guideline supports periodic "clinician-patient risk discussion" to revisit therapy intensity [5].

Scenario 3: Cost or access barriers. Praluent's wholesale acquisition cost exceeds $5,800 per year even after the 2023 list-price reduction by Regeneron. If insurance coverage lapses or prior authorization is denied, an unplanned stop is common. In that setting, a structured approach protects the patient better than an abrupt halt.

Patients who should generally not stop include those with homozygous familial hypercholesterolemia (HoFH), those whose LDL-C remains above target despite maximally tolerated oral therapy, and patients within 12 months of an acute coronary event, given the early separation of event curves in ODYSSEY OUTCOMES (HR 0.85, 95% CI 0.78 to 0.93 for MACE) [1].

Step-by-Step Discontinuation Protocol

No randomized trial has tested a formal "taper" of alirocumab against abrupt cessation, because the every-two-week dosing schedule and long half-life make a traditional taper impractical. The protocol below is derived from the pharmacokinetic profile, guideline recommendations, and the expert consensus published by the National Lipid Association (NLA) [7].

Step 1 (Week 0): Confirm background therapy. Verify the patient is on maximally tolerated statin therapy plus ezetimibe 10 mg daily. If ezetimibe has not been tried, add it 4 to 6 weeks before stopping alirocumab so its effect reaches steady state.

Step 2 (Week 0): Draw baseline labs. Obtain a fasting lipid panel, hepatic function panel, and CK on the day of the last planned alirocumab injection.

Step 3 (Week 0): Administer the final dose. Give the last scheduled alirocumab injection at the patient's current dose (75 mg or 150 mg). Do not halve the dose for a "step-down." A reduced dose provides subtherapeutic PCSK9 inhibition and offers no proven clinical benefit over simply stopping.

Step 4 (Week 4): First recheck. Draw a fasting lipid panel. At four weeks post-last-dose, alirocumab is functionally cleared. The LDL-C value at this visit represents the patient's lipid status on background therapy alone.

Step 5 (Week 12): Confirmatory recheck. A second fasting lipid panel confirms whether the week-4 value was stable or trending upward. If LDL-C is at or below the patient's guideline-based target on both draws, discontinuation can be considered successful.

Step 6: Ongoing annual monitoring. Include a fasting lipid panel at every annual visit. LDL-C can drift upward over years due to aging, weight gain, or dietary changes, independent of the prior PCSK9 inhibitor use.

What to Monitor Beyond LDL-C

LDL-C is the primary metric, but three additional markers deserve attention during the post-discontinuation period.

Lipoprotein(a). Alirocumab reduces Lp(a) by approximately 25% to 30%, a finding confirmed in a prespecified analysis of ODYSSEY OUTCOMES [1]. Patients with elevated baseline Lp(a) (≥50 mg/dL or ≥125 nmol/L) will see that value rise upon stopping. While no approved Lp(a)-lowering therapy exists as of mid-2026, documenting the rebound helps inform future treatment decisions if agents like olpasiran or lepodisiran reach approval [8].

ApoB. Alirocumab lowers apolipoprotein B by 40% to 50%. Because ApoB counts the total number of atherogenic particles, it can reveal residual risk that LDL-C alone may underestimate. The 2019 ESC/EAS guidelines recommend ApoB as a secondary target (<65 mg/dL for very high risk, <80 mg/dL for high risk) [6].

hsCRP. A post hoc analysis of ODYSSEY OUTCOMES showed that patients with both LDL-C <50 mg/dL and hsCRP <2 mg/L on alirocumab had the largest absolute risk reduction [1]. Tracking hsCRP after stopping can help quantify inflammatory residual risk and guide decisions about whether to add therapies like icosapent ethyl.

When to Restart Alirocumab

Restarting is straightforward because there is no immunogenicity concern that would prevent re-initiation. In the ODYSSEY program, anti-drug antibody rates were low (5.1% alirocumab vs. 1.9% placebo) and transient, with no neutralizing antibodies detected in the majority of cases [3].

Dr. Robert Rosenson, director of cardiometabolic disorders at Mount Sinai, has stated: "The PCSK9 inhibitors are among the most immunologically clean biologics we prescribe. There is no clinical reason to avoid restarting after a gap" [9].

Restart alirocumab at the original dose if any of these conditions are met at the week-4 or week-12 recheck:

• LDL-C exceeds the patient's risk-based threshold (≥70 mg/dL for very high ASCVD risk, or ≥55 mg/dL per ESC/EAS criteria) on two consecutive fasting draws despite maximally tolerated oral therapy [5][6].
• A new cardiovascular event or revascularization occurs during the discontinuation window.
• Coronary artery calcium (CAC) progression is documented on interval imaging.

The 2018 AHA/ACC guideline panel wrote: "If a decision is made to initiate a PCSK9 inhibitor, the expected therapeutic response is an approximately 60% further reduction in LDL-C" [5]. That same magnitude of effect is expected upon re-initiation.

Switching to Inclisiran or Bempedoic Acid Instead of Restarting

If the reason for stopping was injection frequency or adherence burden, two alternatives may serve the patient better than restarting alirocumab.

Inclisiran (Leqvio). This small interfering RNA (siRNA) silences hepatic PCSK9 synthesis at the mRNA level. The dosing schedule is twice yearly after two initial loading doses, compared with alirocumab's every-two-week injections. In ORION-10 (N=1,561), inclisiran reduced LDL-C by 52.3% at day 510 [10]. The mechanism differs from alirocumab (intracellular mRNA knockdown vs. extracellular protein binding), but the net effect on LDL-C is comparable.

Bempedoic acid (Nexletol). This oral ATP citrate lyase inhibitor reduced LDL-C by 21.1% vs. placebo in the CLEAR Outcomes trial (N=13,970) and showed a 13% reduction in MACE among statin-intolerant patients [11]. It does not replace a PCSK9 inhibitor's potency, but for patients whose LDL-C gap after discontinuation is modest (10 to 30 mg/dL above target), bempedoic acid plus ezetimibe may close it.

The choice between these options depends on the size of the residual LDL-C gap, the patient's preference for injection frequency versus oral dosing, and insurance formulary coverage.

Special Populations: Discontinuation Considerations

Post-ACS patients within 12 months. The event curves in ODYSSEY OUTCOMES separated early. Stopping alirocumab in the first year after acute coronary syndrome removes protection during the highest-risk window. Dr. Gregory Schwartz, lead investigator of ODYSSEY OUTCOMES, noted: "The benefit of alirocumab was apparent within the first year, consistent with the concept that early intensive LDL lowering confers a disproportionate benefit in the acute post-ACS period" [1].

Familial hypercholesterolemia (heterozygous). Patients with HeFH typically have baseline LDL-C above 190 mg/dL. Even with high-intensity statin plus ezetimibe, most remain well above their <70 mg/dL target. Discontinuation in this group almost invariably triggers a rebound above target and should only be considered if an alternative PCSK9-pathway therapy (inclisiran) is being started simultaneously.

Statin-intolerant patients. Those who cannot tolerate any statin lose their primary LDL-C lowering agent. Alirocumab monotherapy reduced LDL-C by 45.9% in ODYSSEY ALTERNATIVE (N=361) among statin-intolerant patients [12]. Stopping without a replacement leaves these patients with a large, uncontrolled LDL-C burden.

Elderly patients (≥75 years). A prespecified subgroup analysis of ODYSSEY OUTCOMES found consistent MACE benefit in patients aged 65 and older, with no excess adverse events [1]. Age alone is not a reason to discontinue. Shared decision-making should weigh life expectancy, functional status, and polypharmacy burden.

Practical Checklist for Clinicians

Before writing the final alirocumab prescription, verify each item:

1. Patient is on maximally tolerated statin (documented statin intolerance if dose is suboptimal).
2. Ezetimibe 10 mg daily is active or has been trialed and discontinued for documented intolerance.
3. Fasting lipid panel, ApoB, Lp(a), hepatic panel, and CK drawn within 7 days of the last injection.
4. Follow-up visit scheduled at 4 weeks and 12 weeks post-last-dose.
5. Patient educated that LDL-C will rise within 2 to 4 weeks and that this is expected, not a sign of worsening disease.
6. Restart criteria documented in the chart: specific LDL-C threshold, ApoB threshold, or clinical event triggers.
7. For patients on alirocumab 150 mg every 2 weeks, the expected LDL-C rise is 80 to 120 mg/dL above the on-treatment nadir.

The median time from last alirocumab dose to LDL-C plateau on background oral therapy is 28 days, based on the drug's 17-to-20-day half-life and two-half-life washout convention [3].